Skip to content

Wound Assessment Using Spectral Imaging US

Wound Assessment Using Spectral Imaging US

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05415683
Enrollment
400
Registered
2022-06-13
Start date
2022-06-22
Completion date
2024-08-30
Last updated
2024-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetic Foot, Diabetic Foot Ulcer

Brief summary

During the observational, non-interventional study, at Baseline Study Visit (BSV) subjects will be screened and consented. Eligible subjects will undergo imaging with the DeepView device. Pre- and post-debridement images will be obtained (if debridement performed per SOC), as well as reviewing medical history and physical assessments. Additional Study Visits (SVs) will be performed when patient returns to the clinic for Routine Clinic Visit for up to 12 weeks or wound closure. During these visits DeepView imaging will occur pre- and post-debridement, and the status of the subject's treatment will be recorded.

Interventions

DIAGNOSTIC_TESTDV-SSP Imaging

DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.

Sponsors

SpectralMD
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 years old. * Subject has an ulcer, or slow healing wound that is full thickness for at least 4 weeks, below the malleolus, in the presence of Diabetes. * The target ulcer will be the largest ulcer if two or more eligible DFUs are present and will be the only one evaluated in the study. * The target ulcer is planned to undergo standard wound care (SWC) therapy (See 8.6 Standard Wound Care (SWC) Therapy). * Subject understands and is willing to participate in the clinical study and can comply with required visits.

Exclusion criteria

* Target ulcer is deemed by the investigator to be caused by a medical condition other than diabetes. * Target ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer. * Eligible DFU has associated untreated acute osteomyelitis or active infection * Subjects with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids \>10mg daily dose), or cytotoxic chemotherapy. * Subjects on any investigational drug(s) or device(s) within 30 days preceding initial study visit.

Design outcomes

Primary

MeasureTime frameDescription
Data Collection12 weeksThe purpose of this study is to build a database for development and validation of a machine learning (ML) algorithm for diabetic foot ulcer (DFU) healing assessment using images obtained with the Spectral MD DeepView device.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026